Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Expands IP Portfolio via Academic Collaborations

NEW YORK (GenomeWeb News) - Oxford Nanopore Technologies said today that it has signed a number of agreements with academic research institutions in order to expand its intellectual property portfolio around nanopore sensing technology.

The company said it has entered into collaborations with the University of Illinois at Urbana-Champaign, Brown University, Stanford University, Boston University, the University of Cambridge, and the University of Southampton.

While it did not disclose specific technologies covered by any of the licensing agreements, it said that its expanded IP portfolio now includes technology related to a broad range of applications, including DNA base identification using a biological nanopore; characterization of individual polymer molecules based on monomer-interface interactions; addition of adapters to nanopores for sensing; genetically modified nanopores for sensing; the use of molecular motors in combination with nanopores; the use of solid state devices to control movement of polymers; sequencing by means of detection of products of enzymatic action on DNA/RNA using a nanopore; and more.

Oxford Nanopore said that its IP portfolio includes more than 300 issued patents and patent applications in more than 80 patent families.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.